Pharmaceutical Business News

Sangamo Therapeutics and Pfizer Announce Collaboration for Hemophilia A Gene Therapy

Sangamo Therapeutics, Inc. and Pfizer Inc. announced this week, an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo’s four lead product candidates, which Sangamo expects will enter the clinic this quarter. “Sangamo brings deep scientific and technical expertise across multiple […]

Pharmaceutical Business News

Pfizer boosts cancer drug pipeline with $14 billion Medivation deal

BLOOMBERG — Pfizer Inc said on Monday it would buy U.S. cancer drug company Medivation Inc., in a deal valued at about $14 billion, adding blockbuster prostate cancer drug Xtandi to its portfolio. Medivation shares were up 20 percent at $80.56 in premarket trade, just shy of the offer price of $81.50 per share in […]

Pharmaceutical Business News Pharmaceuticals

Pfizer acquires Bamboo Therapeutics to beef up gene therapy arsenal

(Reuters) – Pfizer Inc said it had acquired privately held gene therapy developer Bamboo Therapeutics Inc in a deal worth up to $645 million to boost its presence in the treatment of rare diseases. Research into gene therapy, which aims to insert corrective genes into malfunctioning cells, goes back a quarter of a century but […]

Biotechnology Pharmaceutical Business News

Pfizer to Acquire Anacor Citing Strong fit with Pfizer’s Inflammation and Immunology portfolio

Pfizer Inc. and Anacor Pharmaceuticals, Inc. today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes. The Boards of Directors […]

Pharmaceutical Business News

Called Off: Pharmaceutical Giants Pfizer and Allergan to abandon $212 billion merger

US pharmaceutical giant Pfizer has announced it is abandoning plans for a US $160 billion ($212 billion) merger with Botox maker Allergan, citing new US rules cracking down on tie ups aimed at saving on taxes. The deal with the Irish-based firm would have created the world’s largest pharmaceutical company. Pfizer said in a statement […]